Related Experiment Videos
Third-line chemotherapy for small cell lung cancer
Wouter K de Jong1, Nick H T ten Hacken, Harry J M Groen
1Department of Pulmonology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, NL-9700 RB, Groningen, The Netherlands. w.k.de.jong@int.umcg.nl
Lung Cancer (Amsterdam, Netherlands)
|March 28, 2006
Summary
Third-line chemotherapy shows activity in recurrent small cell lung cancer (SCLC), with a 26% response rate. Patients receiving third-line treatment were younger and had better performance status, indicating potential benefit in select SCLC cases.
Area of Science:
- Oncology
- Medical Oncology
- Pulmonology
Background:
- Efficacy of third-line chemotherapy for small cell lung cancer (SCLC) remains largely unknown.
- Recurrent SCLC often necessitates further treatment lines beyond initial therapies.
- Understanding outcomes of later-line treatments is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy and patient characteristics associated with third-line chemotherapy in recurrent small cell lung cancer (SCLC).
- To determine response rates and survival outcomes for patients receiving third-line SCLC treatment.
Main Methods:
- Retrospective study of 191 SCLC patients treated between January 1996 and July 2004.
- Analysis of patient demographics, treatment history, chemotherapy response, and survival data.
- Focus on the 35 patients (18%) who received third-line chemotherapy.
Main Results:
- Third-line chemotherapy achieved a 26% tumor response rate.
- Median survival from the start of third-line therapy was 5 months.
- Patients receiving third-line therapy were significantly younger, had better ECOG performance scores, and responded better to first-line treatment.
Conclusions:
- Third-line chemotherapy demonstrates activity in approximately one in four small cell lung cancer (SCLC) patients.
- Favorable patient characteristics, including younger age and better performance status, are associated with receiving third-line treatment.
- These findings suggest that third-line chemotherapy can be a viable option for selected SCLC patients with recurrent disease.